Role of bromodomain and extraterminal (BET) proteins in prostate cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of bromodomain and extraterminal (BET) proteins in prostate cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 32, Issue 3, Pages 213-228
Publisher
Informa UK Limited
Online
2023-03-02
DOI
10.1080/13543784.2023.2186851
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PROTAC targeted protein degraders: the past is prologue
- (2022) Miklós Békés et al. NATURE REVIEWS DRUG DISCOVERY
- Evaluation of JQ1 Combined With Docetaxel for the Treatment of Prostate Cancer Cells in 2D- and 3D-Culture Systems
- (2022) Yipeng Xu et al. Frontiers in Pharmacology
- BET bromodomain inhibitors
- (2022) Martin P. Schwalm et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins
- (2022) Joakin O. Mori et al. PROSTATE
- Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2022) Rahul Aggarwal et al. CLINICAL CANCER RESEARCH
- New approaches to targeting epigenetic regulation in prostate cancer
- (2022) Daryl Thompson et al. CURRENT OPINION IN UROLOGY
- BRD4 and MYC : power couple in transcription and disease
- (2022) Aparna Kotekar et al. FEBS Journal
- The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity
- (2022) William K. Storck et al. Frontiers in Endocrinology
- Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer
- (2022) Donglin Ding et al. Nature Communications
- Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
- (2021) Shogo Shigeta et al. MOLECULAR CANCER THERAPEUTICS
- Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
- (2021) Panagiotis J. Vlachostergios et al. Frontiers in Oncology
- Achieving clinical success with BET inhibitors as anti-cancer agents
- (2021) Tatiana Shorstova et al. BRITISH JOURNAL OF CANCER
- Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer
- (2021) Anbarasu Kumaraswamy et al. EUROPEAN UROLOGY
- The role of the deubiquitinating enzyme DUB3/USP17 in cancer: a narrative review
- (2021) Guang-Fei Yang et al. Cancer Cell International
- BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
- (2021) Dae-Hwan Kim et al. CLINICAL CANCER RESEARCH
- Targeting the spectrum of immune checkpoints in prostate cancer
- (2021) Laura A. Sena et al. Expert Review of Clinical Pharmacology
- Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I / II open‐label, dose escalation study
- (2021) Sophie Cousin et al. INTERNATIONAL JOURNAL OF CANCER
- BET Proteins as Attractive Targets for Cancer Therapeutics
- (2021) Joanna Sarnik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion
- (2020) Jianlin Wang et al. Aging-US
- Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
- (2020) Emily J. Faivre et al. NATURE
- Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors
- (2020) Oliver Bechter et al. PHARMACOLOGY & THERAPEUTICS
- MYC protein stability is negatively regulated by BRD4
- (2020) Ballachanda N. Devaiah et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation
- (2020) Omer Gilan et al. SCIENCE
- BET inhibition therapy counteracts cancer cell survival, clonogenic potential and radioresistance mechanisms in rhabdomyosarcoma cells
- (2020) Simona Camero et al. CANCER LETTERS
- A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer
- (2020) Rahul R. Aggarwal et al. CLINICAL CANCER RESEARCH
- BRD4 regulates key transcription factors that drive epithelial–mesenchymal transition in castration-resistant prostate cancer
- (2020) Jordan S. Shafran et al. PROSTATE CANCER AND PROSTATIC DISEASES
- First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
- (2020) Malaka Ameratunga et al. BRITISH JOURNAL OF CANCER
- Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors
- (2020) Ashley Hanlon et al. Hematology-American Society of Hematology Education Program
- BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer
- (2019) Daniel J. Coleman et al. ONCOGENE
- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer
- (2019) Pedro Isaacsson Velho et al. EUROPEAN UROLOGY
- First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
- (2019) Sarina A. Piha-Paul et al. CLINICAL CANCER RESEARCH
- Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors
- (2019) Ying Zhang et al. Expert Opinion on Drug Metabolism & Toxicology
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
- (2019) Wendy Mao et al. Journal for ImmunoTherapy of Cancer
- Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo
- (2018) Gang Shen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
- (2018) Jonathan Welti et al. CLINICAL CANCER RESEARCH
- Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
- (2018) Jeremy Lewin et al. JOURNAL OF CLINICAL ONCOLOGY
- Bromodomain-containing proteins in prostate cancer
- (2018) Alfonso Urbanucci et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- LSD1 activates a lethal prostate cancer gene network independently of its demethylase function
- (2018) Archana Sehrawat et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
- (2018) Xiangyi Li et al. Cell Reports
- Targeting the BRD4-HOXB13 Co-regulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer
- (2018) Niveditha Nerlakanti et al. MOLECULAR CANCER THERAPEUTICS
- DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4
- (2018) Xin Jin et al. MOLECULAR CELL
- ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer
- (2018) Ling Cai et al. MOLECULAR CELL
- Germline DNA Repair Mutations and Response to Hormonal Therapy in Advanced Prostate Cancer
- (2017) Emmanuel S. Antonarakis EUROPEAN UROLOGY
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4
- (2017) Xiangpeng Dai et al. NATURE MEDICINE
- Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
- (2017) Pingzhao Zhang et al. NATURE MEDICINE
- Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
- (2017) Hana Janouskova et al. NATURE MEDICINE
- Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
- (2017) Alfonso Urbanucci et al. Cell Reports
- Treatment strategies for DNA repair-deficient prostate cancer
- (2017) Benjamin A. Teply et al. Expert Review of Clinical Pharmacology
- The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition
- (2016) Goro Sashida et al. JOURNAL OF EXPERIMENTAL MEDICINE
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
- (2016) I. A. Asangani et al. MOLECULAR CANCER RESEARCH
- Potent and selective bivalent inhibitors of BET bromodomains
- (2016) Michael J Waring et al. Nature Chemical Biology
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells
- (2016) Saeed Alghamdi et al. Stem Cell Research & Therapy
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer
- (2015) Gretchen K. Hubbard et al. CANCER RESEARCH
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Non-canonical Bromodomain within DNA-PKcs Promotes DNA Damage Response and Radioresistance through Recognizing an IR-Induced Acetyl-Lysine on H2AX
- (2015) Li Wang et al. CHEMISTRY & BIOLOGY
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- NF- B2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
- (2015) N. Nadiminty et al. MOLECULAR CANCER THERAPEUTICS
- Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
- (2015) Philipp Rathert et al. NATURE
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
- (2015) Siu Chiu Chan et al. NUCLEIC ACIDS RESEARCH
- The oncogene ERG: a key factor in prostate cancer
- (2015) P Adamo et al. ONCOGENE
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.
- (2015) Anastasia Wyce et al. Oncotarget
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation
- (2014) Friederike Itzen et al. NUCLEIC ACIDS RESEARCH
- DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy
- (2014) Franziska Graf et al. PLoS One
- Bromodomains as therapeutic targets in cancer
- (2013) I. Barbieri et al. Briefings in Functional Genomics
- The bromodomain protein Brd4 insulates chromatin from DNA damage signalling
- (2013) Scott R. Floyd et al. NATURE
- Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
- (2013) Lina Gao et al. PLoS One
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- Bromodomain-dependent stage-specific male genome programming by Brdt
- (2012) Jonathan Gaucher et al. EMBO JOURNAL
- High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer
- (2012) Anna Flammiger et al. EUROPEAN JOURNAL OF CANCER
- The bromodomain interaction module
- (2012) Panagis Filippakopoulos et al. FEBS LETTERS
- BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA Polymerase II carboxy-terminal domain
- (2012) B. N. Devaiah et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1
- (2011) Changmeng Cai et al. CANCER CELL
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3
- (2011) S. Rahman et al. MOLECULAR AND CELLULAR BIOLOGY
- PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
- (2011) N. Ilic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genetic alterations and changes in expression of histone demethylases in prostate cancer
- (2010) Hanna E. Suikki et al. PROSTATE
- ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice
- (2009) Scott A. Tomlins et al. EUROPEAN UROLOGY
- Synthetic Lethality — A New Direction in Cancer-Drug Development
- (2009) J. Dirk Iglehart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started